Ingevity director awarded 1,904 deferred stock units

Ingevity Corp director Kevin J. Willis received an equity award of 1,904 deferred stock units.

Rhea-AI Filing Summary

Ingevity Corp director Kevin J. Willis received an equity award of 1,904 deferred stock units. The grant reflects his election to take deferred stock units instead of the usual annual restricted stock unit grant for non-employee directors.

The deferred stock units will vest on April 30, 2027 and will convert into an equal number of Ingevity common shares when his board service ends, under the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. After this award, he holds 11,081 shares directly.

Insider Trade Summary

Grant/Award: 1,904 shares

Grant/Award 1 txn

Insider WILLIS J KEVIN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,904	$0.00	$0.00

Holdings After Transaction: Common Stock — 11,081 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of deferred stock units ("DSUs") issued pursuant to the reporting person's election to receive DSUs in lieu of the annual non-employee director restricted stock unit grant. These DSUs will vest on April 30, 2027 and will settle into an equal number of shares of the issuer's Common Stock upon the reporting person's termination of board service pursuant to the issuer's Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.

Key Figures

Deferred stock units granted: 1,904 units Shares owned after transaction: 11,081 shares Vesting date: April 30, 2027

3 metrics

Deferred stock units granted 1,904 units Award to director Kevin J. Willis on April 30, 2026

Shares owned after transaction 11,081 shares Common stock directly held by Kevin J. Willis after grant

Vesting date April 30, 2027 Vesting date for the 1,904 deferred stock units

Key Terms

deferred stock units ("DSUs"), Amended and Restated Non-Employee Director Deferred Compensation Plan, 2025 Omnibus Incentive Plan, restricted stock unit grant

4 terms

deferred stock units ("DSUs") financial

"Represents a grant of deferred stock units ("DSUs") issued pursuant to the reporting person's election"

Amended and Restated Non-Employee Director Deferred Compensation Plan financial

"upon the reporting person's termination of board service pursuant to the issuer's Amended and Restated Non-Employee Director Deferred Compensation Plan"

2025 Omnibus Incentive Plan financial

"pursuant to the issuer's Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan"

An omnibus incentive plan is a company-wide program that authorizes awards of pay tied to performance and retention—such as stock options, restricted shares, cash bonuses and other rewards—here labeled for the year it was adopted (2025). Investors care because it affects how much ownership can be issued, dilutes existing shareholders, and aligns executives’ and employees’ incentives with company goals, similar to giving team members a stake in the outcome.

restricted stock unit grant financial

"in lieu of the annual non-employee director restricted stock unit grant"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ingevity (NGVT) disclose for director Kevin Willis?

Ingevity disclosed that director Kevin J. Willis received 1,904 deferred stock units as an equity award. He elected to receive these units instead of the standard annual restricted stock unit grant for non-employee directors under the company’s compensation and incentive plans.

How many Ingevity deferred stock units were granted to Kevin Willis?

Kevin Willis was granted 1,904 deferred stock units tied to Ingevity common stock. These units represent compensation for his board service and replace the typical annual restricted stock unit grant normally provided to non-employee directors under the company’s incentive and deferral programs.

When do Kevin Willis’s Ingevity deferred stock units vest and settle?

The 1,904 deferred stock units granted to Kevin Willis will vest on April 30, 2027. After vesting, they will settle into an equal number of Ingevity common shares upon his termination of board service, following the terms of the company’s director deferred compensation plan.

What plans govern Kevin Willis’s deferred stock units at Ingevity (NGVT)?

Kevin Willis’s deferred stock units are issued under Ingevity’s Amended and Restated Non-Employee Director Deferred Compensation Plan and its 2025 Omnibus Incentive Plan. These plans define vesting, settlement into common stock, and the structure of equity compensation for non-employee directors.

How many Ingevity shares does Kevin Willis hold after this Form 4 transaction?

Following the reported grant, Kevin Willis directly holds 11,081 Ingevity common shares. This figure reflects his position after receiving 1,904 deferred stock units, which will later convert into common shares once they vest and his board service ends under the plan terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILLIS J KEVIN

(Last) (First) (Middle)

C/O INGEVITY CORPORATION

4920 O'HEAR AVE, SUITE 400

(Street)

NORTH CHARLESTON SOUTH CAROLINA 29405

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ingevity Corp [ NGVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		A		1,904(1)	A	$0	11,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of deferred stock units ("DSUs") issued pursuant to the reporting person's election to receive DSUs in lieu of the annual non-employee director restricted stock unit grant. These DSUs will vest on April 30, 2027 and will settle into an equal number of shares of the issuer's Common Stock upon the reporting person's termination of board service pursuant to the issuer's Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.

Remarks:

	J. Kevin Willis By: Mavis Huger as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)